<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<?covid-19-tdm?>
<article article-type="brief-report" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Physiol.</journal-id>
<journal-title>Frontiers in Physiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Physiol.</abbrev-journal-title>
<issn pub-type="epub">1664-042X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1203983</article-id>
<article-id pub-id-type="doi">10.3389/fphys.2023.1203983</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Physiology</subject>
<subj-group>
<subject>Brief Research Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>T-cell-derived TNF-&#x3b1; and a cluster of immunological parameters from plasma allow a separation between SARS-CoV-2 convalescent versus vaccinated elite athletes</article-title>
<alt-title alt-title-type="left-running-head">Palmowski et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphys.2023.1203983">10.3389/fphys.2023.1203983</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Palmowski</surname>
<given-names>Jana</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kohnhorst</surname>
<given-names>Sarah</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2311739/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bauer</surname>
<given-names>Pascal</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1128285/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Puta</surname>
<given-names>Christian</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/143680/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haunhorst</surname>
<given-names>Simon</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2049723/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gebhardt</surname>
<given-names>Kristina</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1934518/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Reichel</surname>
<given-names>Thomas</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1683641/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Keller</surname>
<given-names>Christian</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/752541/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huber</surname>
<given-names>Magdalena</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Raifer</surname>
<given-names>Hartmann</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/428841/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kr&#xfc;ger</surname>
<given-names>Karsten</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/956008/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Exercise Physiology and Sports Therapy</institution>, <institution>Institute of Sports Science</institution>, <institution>Justus Liebig University Giessen</institution>, <addr-line>Giessen</addr-line>, <country>Germany</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Center for Tumor and Immunology</institution>, <institution>Institute for Systems Immunology</institution>, <addr-line>Marburg</addr-line>, <country>Germany</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Cardiology and Angiology</institution>, <institution>Justus-Liebig-University Giessen</institution>, <addr-line>Giessen</addr-line>, <country>Germany</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Sports Medicine and Health Promotion</institution>, <institution>Friedrich Schiller University Jena</institution>, <addr-line>Jena</addr-line>, <country>Germany</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Center for Sepsis Control and Care (CSCC)</institution>, <institution>Jena University Hospital</institution>, <institution>Friedrich-Schiller-University Jena</institution>, <addr-line>Jena</addr-line>, <country>Germany</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Center for Interdisciplinary Prevention of Diseases Related to Professional Activities</institution>, <addr-line>Jena</addr-line>, <country>Germany</country>
</aff>
<aff id="aff7">
<sup>7</sup>
<institution>Institute of Virology</institution>, <institution>Philipps University Marburg</institution>, <addr-line>Marburg</addr-line>, <country>Germany</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/474607/overview">Tarak Driss</ext-link>, Universit&#xe9; Paris Nanterre, France</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1374904/overview">Elmo Neuberger</ext-link>, Johannes Gutenberg University Mainz, Germany</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1192812/overview">Erik D. Hanson</ext-link>, University of North Carolina at Chapel Hill, United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Karsten Kr&#xfc;ger, <email>karsten.krueger@sport.uni-giessen.de</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1203983</elocation-id>
<history>
<date date-type="received">
<day>11</day>
<month>04</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>06</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Palmowski, Kohnhorst, Bauer, Puta, Haunhorst, Gebhardt, Reichel, Keller, Huber, Raifer and Kr&#xfc;ger.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Palmowski, Kohnhorst, Bauer, Puta, Haunhorst, Gebhardt, Reichel, Keller, Huber, Raifer and Kr&#xfc;ger</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Guidelines for medical clearing after SARS-CoV-2 infection in elite athletes do not include T-cell immunity aspects despite its relevance in the course of COVID-19 disease. Therefore, we aimed to analyze T-cell-related cytokines before and after <italic>in-vitro</italic> activation of CD4<sup>&#x2b;</sup> T-cells. We sampled professional indoor sports athletes at medical clearing after SARS-CoV-2 infection obtaining clinical, fitness data, and serological data including CD4<sup>&#x2b;</sup> T-cell cytokines. All data were analyzed by principal component analysis and 2 &#xd7; 2 repeated measures ANOVA. CD4<sup>&#x2b;</sup> T-cells were sampled for cell culture activation with anti-CD3/anti-CD28 tetramers. At medical clearing, CD4<sup>&#x2b;</sup> T-cells from convalescent athletes secreted increased levels of TNF-&#x3b1; 72&#xa0;h after <italic>in-vitro</italic> activation compared to vaccinated athletes. IL-18 levels in plasma were elevated and a cluster of parameters differentiated convalescent from vaccinated athletes by 13 parameters at the timepoint of medical clearing. All clinical data indicate infection is resolved, while increased TNF-&#x3b1; may reflect altered proportions of peripheral T-cells as a hangover of infection.</p>
</abstract>
<kwd-group>
<kwd>T-lymphocyte</kwd>
<kwd>SARS-CoV-2</kwd>
<kwd>vaccination</kwd>
<kwd>convalescence</kwd>
<kwd>elite athletes</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Exercise Physiology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Indoor team sports players have a high transmission risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (<xref ref-type="bibr" rid="B15">Jones et al., 2021</xref>; <xref ref-type="bibr" rid="B28">Pauser et al., 2021</xref>) as indoor facilities ameliorate inhalation of respiratory droplets (and thus SARS-CoV-2), which are emitted by talking, coughing, sneezing, and breathing, contributing to viral spread (<xref ref-type="bibr" rid="B39">Tang et al., 2021</xref>; <xref ref-type="bibr" rid="B25">Mutsch et al., 2022</xref>). Acute coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 can be characterized by classical respiratory symptoms such as cough and fever in the mild course of the disease in young patients (<xref ref-type="bibr" rid="B20">Leung, 2021</xref>). The severity of acute coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is mostly mild in young professional athletes and physically active adults (<xref ref-type="bibr" rid="B35">Sallis et al., 2021</xref>; <xref ref-type="bibr" rid="B18">Krzywa&#x144;ski et al., 2022</xref>). However, the infection itself poses a risk, especially for athletes, if they return to sport too early without the infection being completely resolved. For instance, the incidence of cardiac complications such as myocarditis after COVID-19 ranges internationally from 1.1%&#x2013;2.3% among competitive athletes (<xref ref-type="bibr" rid="B13">Halle et al., 2021</xref>). Myocarditis is difficult to diagnose as symptoms are non-specific (<xref ref-type="bibr" rid="B7">Daniels et al., 2021</xref>). Moreover, dysregulation of T-cell subsets is a key factor in myocardial inflammation (<xref ref-type="bibr" rid="B41">Wang and Han, 2020</xref>). The rate itself is relatively low, but myocarditis is one of the leading causes of sports-related sudden cardiac arrest in Germany (<xref ref-type="bibr" rid="B3">Bohm et al., 2021</xref>). Therefore, medical clearing after infection is given a special clinical focus in competitive sports (<xref ref-type="bibr" rid="B29">Phelan et al., 2020</xref>). The analysis of T-cell immunology may strengthen sufficient medical clearing.</p>
<p>Mild courses of disease in young elite athletes are influenced by CD4<sup>&#x2b;</sup> T-cell type 1 (Th1) immune response protecting the infected from developing severe COVID-19 disease (<xref ref-type="bibr" rid="B6">Chen et al., 2022</xref>; <xref ref-type="bibr" rid="B18">Krzywa&#x144;ski et al., 2022</xref>; <xref ref-type="bibr" rid="B24">Moss, 2022</xref>). Th1 differentiation is associated with the secretion of the signature cytokines, such as Interferon-gamma (IFN-&#x3b3;) and tumor necrosis factor-alpha (TNF-&#x3b1;) (<xref ref-type="bibr" rid="B31">Raphael et al., 2015</xref>). SARS-CoV-2&#x2013;specific T-cells of previously infected patients predominantly produce Th1 cytokines (<xref ref-type="bibr" rid="B42">Weiskopf et al., 2020</xref>). Higher polyfunctional TNF-&#x3b1;&#x2b; IFN-&#x3b3;&#x2b; T-cell frequency was also found after vaccination, but it is transient decreasing significantly after 6&#xa0;months (<xref ref-type="bibr" rid="B12">Guerrera et al., 2021</xref>).</p>
<p>While expert guidelines for medical clearing after SARS-CoV-2 infection have been established based on subjective psychological and cardio-pulmonary examinations, objective immunological aspects other than typical clinical blood markers have not yet been considered as parameters for medical clearance and are currently unknown (<xref ref-type="bibr" rid="B10">Elliott et al., 2020</xref>; <xref ref-type="bibr" rid="B43">Wilson et al., 2020</xref>). The relevance of T-cell immunity implies the need for analyzing the athletes for T-cell-related cytokines in plasma and T-cell-activation cytokines within the context of other common clinical parameters. Therefore, the aim of our study was to analyze T-cell-related cytokines before and after <italic>in-vitro</italic> activation of CD4<sup>&#x2b;</sup> T-cells sampled from convalescent and vaccinated indoor sports athletes at medical clearing.</p>
</sec>
<sec sec-type="methods" id="s2">
<title>2 Methods</title>
<sec id="s2-1">
<title>2.1 Participants</title>
<p>All professional athletes are part of the cross-sectional, single-center pilot study obtaining clinical and fitness data from athletes in the handball and ice-hockey pre-seasons (<xref ref-type="bibr" rid="B2">Bauer et al., 2022</xref>). Inclusion criteria were participation in professional indoor sports, no chronic diseases, age between 18 and 30&#xa0;years, and full physical fitness at the immunological testing. All participants were part of the mentioned single-center pilot study and gave additional consent to their participation in this study. Either COVID-19 convalescent athletes (Con) at the time of medical clearing or non-infected controls (Vac) at the time of medical clearing pre-season were included. Due to the high vaccination rates in professional sports, all non-infected athletes were fully vaccinated. Participating athletes were 28.2 &#xb1; 6&#xa0;years with a height of 189.4 &#xb1; 5.4&#xa0;cm and a weight of 95.1 &#xb1; 9.3&#xa0;kg. Their body mass index was 26.5 &#xb1; 1.8&#xa0;kg/m<sup>2</sup>. Subjects were experienced professional athletes with a mean training time of 1,152&#xa0;min per week.</p>
</sec>
<sec id="s2-2">
<title>2.2 Study-design</title>
<p>We used an experimental study design performing cell culture analysis to obtain immunological data. This study arm was integrated into an observational controlled single-center pilot study design obtaining a broad panel of hematological and cardiovascular parameters as part of pre-season medical clearing (<xref ref-type="bibr" rid="B2">Bauer et al., 2022</xref>). This data was integrated into our systemic analysis of the immunological study arm. This additional study arm was approved by the Institutional Review Board of the Justus-Liebig-University Giessen (AZ183/20, 16 March 21) following the ethical guidelines of the declaration of Helsinki. Written informed consent was provided by all participants. Convalescent athletes were invited to the laboratory 14&#xa0;days after the positive polymerase chain reaction (PCR) test result following the German quarantine regulations and available guidelines for medical clearing (<xref ref-type="bibr" rid="B37">Schellhorn et al., 2020</xref>). Control athletes were investigated following the same procedure after their off-season to not interfere with exercise-related immune disruption by high-intensive exercise training. For an overview of our workflow see <xref ref-type="fig" rid="F1">Figure 1A</xref>.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Workflow of this Study <bold>(A)</bold>. Concentrations of IgG antibodies against Spike were measured in plasma <bold>(B)</bold>. Total nucleocapsid protein-specific antibodies (NCP) were measured in plasma. One athlete belonging to Con did not show NCP antibodies. C.O.I. stands for cut-off-index which was set at on for this test. The dashed line indicates the detection limit <bold>(C)</bold>. PCA were calculated including all immunological and clinical parameters <bold>(D)</bold> as well as excluding all parameters, which show a statistical difference of <italic>p</italic> &#x2264; 0.1 <bold>(E)</bold>. For all parts of the figure, Con means cells were isolated from convalescent athletes. Vac means T-cells were isolated from non-infected, COVID-19-vaccinated athletes (Con <italic>N</italic> &#x3d; 7, Vac <italic>N</italic> &#x3d; 8). Significance was determined by the Mann-Whitney test (<italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001). Data are shown as mean &#xb1; SEM.</p>
</caption>
<graphic xlink:href="fphys-14-1203983-g001.tif"/>
</fig>
</sec>
<sec id="s2-3">
<title>2.3 Immunological data</title>
<p>For immunological analysis, CD4<sup>&#x2b;</sup> T-cells, serum, and plasma were obtained from seven convalescent and eight non-infected fully vaccinated men. Fully vaccinated refers to the German definition at the time from May to August 2022; meaning two doses for BNT162b2 (Pfizer-BioNTech), two doses for ChAdOx1-S (Oxford-AstraZeneca), and one dose for Ad26.COV2.S COVID-19 (Johnson and Johnson/Janssen). T-cells were isolated from peripheral blood via density gradient centrifugation and subsequent negative selection using EasySep&#x2122; magnetic particles (Stemcell Technologies, Vancouver, BC, Canada) as described by our group before (<xref ref-type="bibr" rid="B27">Palmowski et al., 2021</xref>). Isolated CD4<sup>&#x2b;</sup> were activated with anti-CD3/anti-CD28 stimulating tetramers (Stemcell Technologies, Vancouver, BC, Canada) or remained non-stimulated as controls. Cultures were maintained in IL-2 (Stemcell Technologies, Vancouver, BC, Canada) containing medium supplemented by 10% human AB-serum (Pan-Biotech, Aidenbach, Germany) for 72&#xa0;h until harvest. Cell number, viability, and cell diameter were measured by CASY<sup>&#xae;</sup> Cell Counter (OLSOmni Life Science, Bremen, Germany).</p>
<p>Frozen plasma was thawed, labeled using LEGENDplex Multi-Analyte Flow Assay kit &#x201c;Human Inflammation Panel 1&#x201d; (BioLegend, San Diego, CA), and measured by flow cytometry (BD FACSAria&#x2122; III flow cytometer). Raw data were analyzed by LEGENDplex&#x2122; data analysis software (BioLegend, San Diego, CA). Antibody titers were analyzed using the Elecsys anti-SARS-CoV-2 assay on the cobas 601 (Roche, Rotkreuz, Switzerland). Frozen supernatants were thawed and labeled for IFN-&#x3b3;, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13. IL-17A, and TNF-&#x3b1; using a Luminex assay (Bio-Techne Ltd., Abingdon, Oxon, United Kingdom) and following the manufacturer&#xb4;s instructions. Plasma was analyzed by the Luminex MAGPIX system (Luminex Corporation, Austin, TX, United States).</p>
</sec>
<sec id="s2-4">
<title>2.4 Clinical and fitness data</title>
<p>All athletes completed the pre-participation questionnaire of the European Federation of Sports Medicine Associations including questions related to health, medication, supplementation, exercise history, and exercise volume. Clinical and fitness data was sampled during the pre-season of handball and ice hockey, and return-to-sport as described before (<xref ref-type="bibr" rid="B2">Bauer et al., 2022</xref>). As athletes completed electrocardiographic examinations including a stress test on the bike until subjective exhaustion as part of the medical clearing. Performance was calculated as the participants&#x2019; wattage at exhaustion in relation to their body weight. As part of the clinical examination laboratory blood parameters, such as blood sugar, HbA1c, electrolyte, iron metabolism, coagulation, liver, kidney, muscular enzyme, lipid, and thyroid hormone status were collected. All participants were attested with full physical fitness at the immunological testing.</p>
</sec>
<sec id="s2-5">
<title>2.5 Statistical analysis</title>
<p>Bioinformatics analysis was performed using RStudio running R software (4.1.2). All data are presented as mean &#xb1; standard deviation (SD). Data were tested for normal distribution by the Shapiro-Wilk test. To determine the effect of SARS-CoV-2 infection at the time of immunological testing, Wilcoxon signed-rank tests were conducted with all pre- and post-clinical, immunological, and fitness data of all 15 athletes after infection or vaccination. To visualize the differences between the SARS-CoV-2 infected and SARS-CoV-2 vaccinated group we performed a PCA (package factoextra) with 59 clinical and immunological parameters and one with clinical and immunological parameters that had a statistical difference of <italic>p</italic> &#x2264; 0.1. R-based graphs were created with packages ggplot2 3.4.1 and ggpubr 0.6.0.</p>
<p>Cell culture results were analyzed by a 2-by-2 repeated-measures ANOVA with activation status as the within factor (control cells vs. activated cells) and group (Con vs. Vac) as the between factor. Bonferroni post-hoc test was used. For analysis and visualization we used GraphPad Prism version 5 (San Diego, CA, United States). Data were shown as mean &#xb1; standard deviation. The same statistics were also applied for the comparison between baseline and follow-up clinical parameters changing the within factor to time. The significance level was set at <italic>p</italic> &#x3c; 0.05.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>3 Results</title>
<sec id="s3-1">
<title>3.1 Immunological parameters</title>
<p>Analysis of SARS-CoV-2 specific antibodies show no significant differences between Con and Vac in spike-specific plasma IgG antibody titers (<xref ref-type="fig" rid="F1">Figure 1B</xref>). However, in contrast to Con, Vac are non-reactive against the nucleocapsid protein (NCP) (<xref ref-type="fig" rid="F1">Figure 1C</xref>). One athlete belonging to Con did not show NCP antibodies. At the time point of our immunological analysis, there was no significant difference in pro-inflammatory plasma cytokines except for IL-18 (<xref ref-type="table" rid="T1">Table 1</xref>). IL-18 plasma level was increased in Vac compared to Con.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Pro-inflammatory cytokines in plasma at the time point of immunological analysis. Plasma was measured using LEGENDplex Multi-Analyte Flow Assay kit &#x201c;Human Inflammation Panel 1&#x201d; (BioLegend, San Diego, CA) and flow cytometry (BD FACSAria&#x2122; III flow cytometer). Wilcoxon signed-rank tests were conducted. (<italic>p</italic> &#x3c; 0.05). Data are shown as mean &#xb1; SD. Significant findings are highlighted in bold letters.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left"/>
<th colspan="2" align="center">Con</th>
<th colspan="2" align="center">Vac</th>
<th align="left"/>
</tr>
<tr>
<th align="left"/>
<th align="left">Mean [pg/ml]</th>
<th align="left">SD [pg/m]</th>
<th align="left">Mean [pg/ml]</th>
<th align="left">SD [pg/ml]</th>
<th align="left">p-value</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">IL-1&#x3b2;</td>
<td align="left">12.57</td>
<td align="left">5.54</td>
<td align="left">13.62</td>
<td align="left">4.44</td>
<td align="left">0.424</td>
</tr>
<tr>
<td align="left">IFN-&#x3b1;2</td>
<td align="left">18.42</td>
<td align="left">12.37</td>
<td align="left">21.25</td>
<td align="left">17.47</td>
<td align="left">0.897</td>
</tr>
<tr>
<td align="left">IFN-&#x3b3;</td>
<td align="left">7.07</td>
<td align="left">5.43</td>
<td align="left">6.30</td>
<td align="left">4.17</td>
<td align="left">1.000</td>
</tr>
<tr>
<td align="left">TNF-&#x3b1;</td>
<td align="left">25.39</td>
<td align="left">23.71</td>
<td align="left">34.75</td>
<td align="left">34.08</td>
<td align="left">0.523</td>
</tr>
<tr>
<td align="left">MCP-1</td>
<td align="left">20.23</td>
<td align="left">17.63</td>
<td align="left">24.11</td>
<td align="left">23.28</td>
<td align="left">0.698</td>
</tr>
<tr>
<td align="left">IL-6</td>
<td align="left">8.87</td>
<td align="left">3.87</td>
<td align="left">11.15</td>
<td align="left">7.45</td>
<td align="left">0.436</td>
</tr>
<tr>
<td align="left">IL-8</td>
<td align="left">38.70</td>
<td align="left">11.95</td>
<td align="left">60.39</td>
<td align="left">35.22</td>
<td align="left">0.369</td>
</tr>
<tr>
<td align="left">IL-10</td>
<td align="left">10.09</td>
<td align="left">7.65</td>
<td align="left">13.50</td>
<td align="left">9.04</td>
<td align="left">0.513</td>
</tr>
<tr>
<td align="left">IL-12p70</td>
<td align="left">7.22</td>
<td align="left">4.13</td>
<td align="left">6.64</td>
<td align="left">1.84</td>
<td align="left">0.887</td>
</tr>
<tr>
<td align="left">IL-17A</td>
<td align="left">2.98</td>
<td align="left">1.93</td>
<td align="left">2.87</td>
<td align="left">1.41</td>
<td align="left">0.796</td>
</tr>
<tr>
<td align="left">IL-18</td>
<td align="left">244.70</td>
<td align="left">64.58</td>
<td align="left">368.75</td>
<td align="left">100.38</td>
<td align="left">
<bold>0.030</bold>
</td>
</tr>
<tr>
<td align="left">IL-23</td>
<td align="left">9.66</td>
<td align="left">8.05</td>
<td align="left">20.26</td>
<td align="left">25.59</td>
<td align="left">0.887</td>
</tr>
<tr>
<td align="left">IL-33</td>
<td align="left">190.34</td>
<td align="left">166.67</td>
<td align="left">160.58</td>
<td align="left">105.87</td>
<td align="left">0.898</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-2">
<title>3.2 Principal component analysis</title>
<p>Principal component analysis revealed that all immunological and clinical parameters allow a slight separation between Con and Vac by systemic analysis at the time of immunological testing, while 13 parameters separated infected from vaccinated samples significantly (<xref ref-type="fig" rid="F1">Figures 1D, E</xref>). These were: Creatinine, glomerular filtration rate (GFR), glutamic oxaloacetic transaminase, potassium, creatine kinase, glycated hemoglobin (HbA1c), triiodothyronine, ferritin, myoglobin, cardiovascular parameters (diastolic aortic pressure, mean aortic pressure, and diastolic brachial blood pressure), and TNF-&#x3b1; derived from activated T-cell culture (<xref ref-type="table" rid="T2">Table 2</xref>).</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Selected parameters at the time point of immunological testing that were identified by PCA. All parameters are measured in plasma despite TNF-&#x3b1; that was measured in cell culture supernatants. Data are shown as mean &#xb1; SD. Significant findings are highlighted in bold letters.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left"/>
<th colspan="2" align="center">Con</th>
<th colspan="2" align="center">Vac</th>
<th align="left"/>
</tr>
<tr>
<th align="left"/>
<th align="left">Mean</th>
<th align="left">SD</th>
<th align="left">Mean</th>
<th align="left">SD</th>
<th align="left">p (post)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">Diastolic aortic pressure</td>
<td align="left">74.43</td>
<td align="left">8.89</td>
<td align="left">64.63</td>
<td align="left">6.65</td>
<td align="left">
<bold>0.036</bold>
</td>
</tr>
<tr>
<td align="center">Mean aortic pressure</td>
<td align="left">85.86</td>
<td align="left">7.66</td>
<td align="left">77.33</td>
<td align="left">6.26</td>
<td align="left">
<bold>0.028</bold>
</td>
</tr>
<tr>
<td align="center">Creatinine</td>
<td align="left">0.90</td>
<td align="left">0.08</td>
<td align="left">1.03</td>
<td align="left">0.07</td>
<td align="left">
<bold>0.015</bold>
</td>
</tr>
<tr>
<td align="center">Glomerular filtration rate</td>
<td align="left">105.81</td>
<td align="left">9.24</td>
<td align="left">94.49</td>
<td align="left">8.64</td>
<td align="left">
<bold>0.049</bold>
</td>
</tr>
<tr>
<td align="center">Ferritin</td>
<td align="left">206.14</td>
<td align="left">52.27</td>
<td align="left">126.25</td>
<td align="left">92.03</td>
<td align="left">
<bold>0.032</bold>
</td>
</tr>
<tr>
<td align="center">Triiodothyronine</td>
<td align="left">3.53</td>
<td align="left">0.20</td>
<td align="left">3.21</td>
<td align="left">0.31</td>
<td align="left">
<bold>0.040</bold>
</td>
</tr>
<tr>
<td align="center">Creatine kinase</td>
<td align="left">117.29</td>
<td align="left">41.05</td>
<td align="left">371.13</td>
<td align="left">305.08</td>
<td align="left">
<bold>0.013</bold>
</td>
</tr>
<tr>
<td align="center">Myoglobin</td>
<td align="left">65.29</td>
<td align="left">92.10</td>
<td align="left">50.00</td>
<td align="left">27.09</td>
<td align="left">
<bold>0.042</bold>
</td>
</tr>
<tr>
<td align="center">TNF-alpha</td>
<td align="left">6083.75</td>
<td align="left">122.94</td>
<td align="left">5845.88</td>
<td align="left">127.15</td>
<td align="left">
<bold>0.007</bold>
</td>
</tr>
<tr>
<td align="center">Diastolic brachial blood pressure</td>
<td align="left">72.86</td>
<td align="left">9.25</td>
<td align="left">64.13</td>
<td align="left">5.84</td>
<td align="left">0.064</td>
</tr>
<tr>
<td align="center">Glycated hemoglobin</td>
<td align="left">5.43</td>
<td align="left">0.27</td>
<td align="left">5.13</td>
<td align="left">0.35</td>
<td align="left">0.071</td>
</tr>
<tr>
<td align="center">Potassium</td>
<td align="left">4.16</td>
<td align="left">0.26</td>
<td align="left">3.85</td>
<td align="left">0.33</td>
<td align="left">0.080</td>
</tr>
<tr>
<td align="center">Glutamic oxaloacetic transaminase</td>
<td align="left">19.00</td>
<td align="left">5.00</td>
<td align="left">28.13</td>
<td align="left">12.24</td>
<td align="left">0.091</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-3">
<title>3.3 Activated cell culture</title>
<p>A significant activation-driven effect was detectable for total cell count and cell diameter of the <italic>in vitro</italic> experiments, but not for viability and survival. We calculated cell survival via the formula: Viability &#x3d; (100%&#x2212; viability before culture) &#x2b; viability after cell culture. Con and Vac measurements were comparable 72-h post-activation (<xref ref-type="fig" rid="F2">Figures 2A&#x2013;D</xref>; <xref ref-type="sec" rid="s10">Supplementary Table S1</xref>). Likewise, a significant effect for all measured T-cell signature cytokines was found after activation, namely, for IFN-&#x3b3;, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17A, and TNF-&#x3b1; (<xref ref-type="sec" rid="s10">Supplementary Table S1</xref>). However, only the levels for TNF-&#x3b1; significantly differed between Vac vs. Con. Supernatants from Con CD4<sup>&#x2b;</sup> T-cells showed increased TNF-a levels compared to the Vac after the Bonferroni posttest with <italic>p</italic> &#x3e; 0.001 (<xref ref-type="fig" rid="F2">Figure 2E</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>T-cell count <bold>(A)</bold>, mean diameter <bold>(B)</bold>, viability <bold>(C)</bold>, and survival <bold>(D)</bold> after activation of 1 million CD4<sup>&#x2b;</sup> T-cells using anti-CD3/anti-CD28 tetrameres. T cell-derived TNF-&#x3b1; levels were measured after 72&#xa0;h post activation of 1 million CD4<sup>&#x2b;</sup> T-cells with anti-CD3/anti-CD28 tetramers (Stemcell Technologies, Vancouver, BC, Canada) or after 72&#xa0;h in non-activated controls <bold>(E)</bold>. Performance was calculated from the ECG stress test as the participants&#x2019; wattage at exhaustion in relation to their body weight <bold>(F)</bold>. Cell culture supernatants such as TNF-&#x3b1; were analyzed using a commercially available human Magnetic Luminex Assay (Bio-Techne, Abingdon, United Kingdom) by Magpix Luminex Instrument (Luminex Corp, Austin, TX, United States). Significance was determined by a repeated-measures 2 &#xd7; 2 ANOVA and Bonferroni posttest. TNF-&#x3b1; levels were significant for activation status, group, and interaction, with a significant difference between Con and Vac for post-activation TNF-&#x3b1; levels showed by Bonferroni posttest (&#x2a;<italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001). Con refers to T-cells that were isolated from convalescent athletes, and Vac refers to T-cells that were isolated from vaccinated athletes (Con <italic>N</italic> &#x3d; 7, Vac <italic>N</italic> &#x3d; 8). Data are shown as mean &#xb1; SEM.</p>
</caption>
<graphic xlink:href="fphys-14-1203983-g002.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>3.4 Clinical parameters</title>
<p>All laboratory parameters were within the physiologic range. Two-way ANOVA showed a significant effect for time for aortic diastolic and systolic aortic blood pressure for all athletes, Vac and Con, at return-to-sport. Blood pressure was higher at immunological sampling. An effect for time was also found for lactate dehydrogenase with significantly lower mean values both at immunological sampling. A significant effect for the condition was found on HbA1c and free triiodothyronine and a significant interaction of time and condition was shown for potassium, magnesium, and creatinine (<xref ref-type="sec" rid="s10">Supplementary Table S2</xref>).</p>
</sec>
<sec id="s3-5">
<title>3.5 Fitness parameters</title>
<p>Exercise testing revealed a lower performance/weight ratio for Con compared to Vac. Of note, the individual performance does not fall below pre-season performance after quarantine (<xref ref-type="fig" rid="F1">Figure 2F</xref>).</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>4 Discussion</title>
<p>The present work evaluated T-cell-related cytokines before and after <italic>in-vitro</italic> activation of CD4<sup>&#x2b;</sup> T-cells sampled from convalescent and vaccinated indoor sports athletes to assess signatures of clinical and immunological parameters in elite athletes who have passed a SARS-CoV-2 infection. There were no elevated levels of inflammatory cytokines in the plasma of Con compared to Vac. Also, no immune disturbance in Con T-cells in terms of activation with anti-CD3/anti-CD28 tetrameres was found. <italic>In vitro</italic> cultivated CD4<sup>&#x2b;</sup> T-cells showed the expected signs of T-cell activation such as increased cell number, cell diameter, and increased production of T-cell signature cytokines. However, there are indications that can be interpreted as residual infection indicators, such as an increased TNF-&#x3b1; production in activated T-cells and reduced performance.</p>
<sec id="s4-1">
<title>4.1 Increased TNF-&#x3b1; production of CD4<sup>&#x2b;</sup> T-cells in Con athletes after activation</title>
<p>After T-cell activation, TNF-&#x3b1; production was significantly increased by cells of Con compared to Vac, whereby overall T-cell number, mean cell viability, total cell count, and cell diameter in the <italic>in vitro</italic> experiments were comparable between both groups. Mobilization of peripheral T-cells may have influenced our <italic>in vitro</italic> cell culture results. Increased TNF-&#x3b1; level in Con after activation may be biased by a type 1 differentiation as TNF-&#x3b1; is a classical type 1 cytokine and indicates a higher pro-inflammatory response (<xref ref-type="bibr" rid="B21">Mahnke et al., 2013</xref>). TNF-&#x3b1; is produced by type 1 cells, which are possibly still present in greater numbers in peripheral blood after an effective immune response and release TNF-&#x3b1; after activation (<xref ref-type="bibr" rid="B34">Rosendahl Huber et al., 2014</xref>). In line with that, it was shown for other convalescent patients that SARS-CoV-2&#x2013;specific T-cells predominantly produce Th1 cytokines (<xref ref-type="bibr" rid="B42">Weiskopf et al., 2020</xref>). At the same time, the difference in TNF-&#x3b1; level could also be caused by metabolic disturbance of T-cell glycolysis in Vac. <italic>In vitro</italic> studies with isolated CD4<sup>&#x2b;</sup> have shown, glycolytic inhibitor 2-deoxy-glucose reduces TNF-&#x3b1; production (<xref ref-type="bibr" rid="B32">Renner et al., 2015</xref>). Overall, the function of CD4<sup>&#x2b;</sup> T-cells after activation is not reduced after SARS-CoV-2 infection in athletes. Their peripheral cells react to tetramere activation more sensitively than Vac CD4<sup>&#x2b;</sup> T-cells.</p>
</sec>
<sec id="s4-2">
<title>4.2 Increased pro-inflammatory IL-18 in Vac</title>
<p>An elevated level of pro-inflammatory plasma cytokine was found for IL-18 in Vac participants compared to Con. IL-18 is secreted by various cell types such as macrophages, B cells, dendritic cells, keratinocytes, and even type 2 muscle fiber (<xref ref-type="bibr" rid="B23">Mee et al., 2000</xref>; <xref ref-type="bibr" rid="B30">Plomgaard et al., 2005</xref>; <xref ref-type="bibr" rid="B9">Dinarello et al., 2013</xref>). The cytokine is known for its pro-inflammatory properties. It is activated in an NLPR3 inflammasome-dependent manner and enhances Th1 cell activation (<xref ref-type="bibr" rid="B22">Mantovani et al., 2019</xref>). We measured similar IL-18 levels for Con athletes compared to other studies that measured IL-18 in healthy young men (<xref ref-type="bibr" rid="B19">Leick et al., 2007</xref>; <xref ref-type="bibr" rid="B16">Khakroo Abkenar et al., 2019</xref>). So, we conclude, Con are fully recovered in terms of inflammatory mediators available in plasma. The elevated plasma IL-18 level in Vac could be exercise-related because this cytokine is highly sensitive to resistance exercise training and detraining (<xref ref-type="bibr" rid="B26">Nikseresht et al., 2016</xref>; <xref ref-type="bibr" rid="B16">Khakroo Abkenar et al., 2019</xref>). Young men showed significantly higher plasma IL-18 accompanied by higher IL-1&#xdf; levels immediately after acute high-intensity exercise and after 12&#xa0;weeks of high-intensity exercise training (<xref ref-type="bibr" rid="B16">Khakroo Abkenar et al., 2019</xref>). As we found no increase in IL-1&#xdf; plasma levels and Vac were included after the off-season, an effect of high-intensity exercise training on IL-18 level is unlikely. There may be an effect of detraining on Vac that were included after their full off-season and not merely 14&#xa0;days post-quarantine. Type 2 muscle fiber number can be maintained within the first initial weeks of detraining. However, a shift to more oxidative fibers in strength athletes is found after 8&#xa0;weeks of detraining (<xref ref-type="bibr" rid="B5">Bruton, 2002</xref>). Potentially this loss of type-2 muscle fiber is attributed to higher IL-18 levels in Vac (<xref ref-type="bibr" rid="B26">Nikseresht et al., 2016</xref>). Of note, IL-18 levels were also increased in mRNA-vaccinated patients that acquired myopericarditis and psychiatric disorders such as major depression and panic disorder (<xref ref-type="bibr" rid="B17">Kokai et al., 2002</xref>; <xref ref-type="bibr" rid="B44">Won et al., 2022</xref>).</p>
</sec>
<sec id="s4-3">
<title>4.3 Residual infection markers within normal range differentiate Con and Vac athletes</title>
<p>While systemic inflammation of Con athletes based on pro-inflammatory cytokines was resolved, there may still be other residual signs of infection, as indicated by the systemic analysis at medical clearing for ferritin, GFR, and blood pressure. Increased ferritin is common for viral infections (<xref ref-type="bibr" rid="B38">Slaats et al., 2016</xref>). Ferritin represents an acute phase protein that is elevated both generally in viral infections and specifically in COVID-19 (<xref ref-type="bibr" rid="B40">Vlahakos et al., 2021</xref>). Most likely, residual ferritin may be caused by the physiological apoptosis of iron-depleted immune cells (<xref ref-type="bibr" rid="B1">Arigony et al., 2013</xref>). GFR might be attributed to increased blood pressure. In context, the other study arm including professional athletes has found an increased heart rate-corrected augmentation index for Con reflecting lower arterial stiffness (<xref ref-type="bibr" rid="B2">Bauer et al., 2022</xref>). Interpreting blood pressure results, one should include emotional adrenergic-related distress caused by quarantine (<xref ref-type="bibr" rid="B8">di Cagno et al., 2020</xref>) and its influence on T-cells. Immunologically, sympathetic stress also regulates T-cell function via the beta2-adrenergic receptor (&#x3b2;2AR) with a potential to alter T-cell activation (<xref ref-type="bibr" rid="B11">Fan and Wang, 2009</xref>). Under psychological stressors, humans mobilize particularly peripheral T-cells expressing CXCR3 and CCR5 that sensitively react to chemotactic signals of inflamed endothelial cells (<xref ref-type="bibr" rid="B4">Bosch et al., 2003</xref>). However, this mobilization likely is not able to solely explain differences in T-cell activation as blood pressure of Con and Vac both increased across time as indicated by the 2-by-2 ANOVA results.</p>
</sec>
<sec id="s4-4">
<title>4.4 Lower cardiovascular fitness level in Con</title>
<p>Our data shows the Con&#x2019;s cardiopulmonary performance in watt/kg was lower compared to Vac, though still higher than at pre-season. The COVID-19 detraining effect was not below baseline levels at pre-season. Lower performance levels come as no surprise, as performance-limiting factors, for instance, muscular capillarization, are known to decrease in only 2&#xa0;weeks of detraining even in healthy athletes (<xref ref-type="bibr" rid="B5">Bruton, 2002</xref>). Performance decline has been mainly attributed to changes in hemodynamics and neuromuscular adaptations, such as maximal oxygen consumption or muscle strength at maintained muscle mass (<xref ref-type="bibr" rid="B6">Chen et al., 2022</xref>). In line, a recent COVID-19 study including soccer players also found a decline in high-intensity acceleration performance indicating a lower anaerobic threshold (<xref ref-type="bibr" rid="B36">Savicevic et al., 2021</xref>).</p>
</sec>
<sec id="s4-5">
<title>4.5 Limitations</title>
<p>Current vaccines use the spike protein as a target antigen structure, consequently, a spike-specific immunity is induced. After the infection, the immune response is directed against all viral proteins and not only against the spike protein. Thus, only people who were infected with the virus should have NCP-specific antibodies (<xref ref-type="bibr" rid="B14">Jalkanen et al., 2021</xref>). We assumed no unknown infection in the vaccinated control group. However, one Con was non-reactive against NCP, therefore it cannot be ruled out there may be also Vac who had an infection with COVID-19 earlier without building NCP. Further, we cannot exclude, that differences between Con and Vac result from a selection bias. Athletes for this study were selected from the same teams indicating that naturally infected athletes (Con) may have lower immune competence compared to non-infected athletes playing on the same team (Vac).</p>
<p>Unfortunately, our study lacks a control group of non-vaccinated elite athletes and the sample size is low due to the laborious experimental design. This suggests caution when interpreting the findings. Due to the high vaccination rate over the course of the study and a high number of early infected athletes in indoor sports, non-vaccinated elite athletes were not available at the time of sampling in 2021. Although all athletes participating had a reduced physical activity level before the immunological study part, groups may differ by activity level at least 14&#xa0;days before measurement as convalescent athletes are more limited to physical activity due to quarantine regulations. Interpreting our result, one should take caution of the different training phases the athletes were at before their time off practice. This may have influenced the differences in IL-18 plasma levels. <italic>In vivo</italic>, activation of T-cells would likely be influenced by higher IL-18 levels, while our <italic>in vitro</italic> cell culture was supplemented by non-autologous human AB-serum causing cytokine-wise equal cell culture conditions. IL-18 would likely induce Th1 T-cells after activation (<xref ref-type="bibr" rid="B33">Robinson and O&#x2019;Garra, 2002</xref>).</p>
</sec>
</sec>
<sec id="s5">
<title>5 Conclusion</title>
<p>T-cell-related immunological aspects other than typical clinical blood markers have not been investigated at medical clearance in Con after COVID-19 yet. Overall, caution is needed in interpreting our results given the small sample size. Our data shows expert-guided medical clearing after COVID-19 is sufficient to bring immunological parameters back to baseline. Con even have a higher inflammatory response to T-cell activation compared to Vac, indicated by higher TNF-a levels. If this is caused by Th1 response and a transient residual sign of infection, should be investigated in future studies. Despite the resolution of inflammation, athletes and coaches should take into account that athletes&#x2019; T-cells may act more sensitive to immune activation after SARS-CoV-2 infection up to medical clearance.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s11">Supplementary Material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s7">
<title>Ethics statement</title>
<p>The studies involving human participants were reviewed and approved by Institutional Review Board of the Justus-Liebig-University Giessen (AZ183/20, 16th March 21). The patients/participants provided their written informed consent to participate in this study.</p>
</sec>
<sec id="s8">
<title>Author contributions</title>
<p>Conceptualization, PB, JP, KG, TR, MH, and KK; data collection, JP, KG, TR, MH SK, and PB, data analysis: SK, HR, MH, CK, and JP visualization, SK und JP, writing, SH, CP, JP, and KK; supervision KK and HR. All authors contributed to the article and approved the submitted version.</p>
</sec>
<ack>
<p>We thank all participants who took part in the immunological testing.</p>
</ack>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphys.2023.1203983/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphys.2023.1203983/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.DOCX" id="SM1" mimetype="application/DOCX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arigony</surname>
<given-names>A. L. V.</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>I. M.</given-names>
</name>
<name>
<surname>Machado</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bordin</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Bergter</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pr&#xe1;</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>The influence of micronutrients in cell culture: A reflection on viability and genomic stability</article-title>. <source>Biomed. Res. Int.</source> <volume>2013</volume>, <fpage>597282</fpage>&#x2013;<lpage>597322</lpage>. <pub-id pub-id-type="doi">10.1155/2013/597282</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauer</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kraushaar</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>D&#xf6;rr</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Keranov</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nef</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hamm</surname>
<given-names>C. W.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Vascular alterations among male elite athletes recovering from SARS-CoV-2 infection</article-title>. <source>Sci. Rep.</source> <volume>12</volume> (<issue>1</issue>), <fpage>8655</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-12734-z</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bohm</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Scharhag</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Egger</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tischer</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Niederseer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schmied</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Sports-related sudden cardiac arrest in Germany</article-title>. <source>Can. J. Cardiol.</source> <volume>37</volume> (<issue>1</issue>), <fpage>105</fpage>&#x2013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.cjca.2020.03.021</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bosch</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Berntson</surname>
<given-names>G. G.</given-names>
</name>
<name>
<surname>Cacioppo</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Dhabhar</surname>
<given-names>F. S.</given-names>
</name>
<name>
<surname>Marucha</surname>
<given-names>P. T.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Acute stress evokes selective mobilization of T cells that differ in chemokine receptor expression: A potential pathway linking immunologic reactivity to cardiovascular disease</article-title>. <source>Brain Behav. Immun.</source> <volume>17</volume> (<issue>4</issue>), <fpage>251</fpage>&#x2013;<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1016/s0889-1591(03)00054-0</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruton</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Muscle plasticity</article-title>. <source>Physiotherapy</source> <volume>88</volume> (<issue>7</issue>), <fpage>398</fpage>&#x2013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1016/s0031-9406(05)61265-5</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>T. Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Two weeks of detraining reduces cardiopulmonary function and muscular fitness in endurance athletes</article-title>. <source>Eur. J. Sport Sci.</source> <volume>22</volume> (<issue>3</issue>), <fpage>399</fpage>&#x2013;<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1080/17461391.2021.1880647</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daniels</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Rajpal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Greenshields</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Rosenthal</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Terrin</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: Results from the big ten COVID-19 cardiac registry</article-title>. <source>JAMA Cardiol.</source> <volume>6</volume> (<issue>9</issue>), <fpage>1078</fpage>&#x2013;<lpage>1087</lpage>. <pub-id pub-id-type="doi">10.1001/jamacardio.2021.2065</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>di Cagno</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Buonsenso</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Baralla</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Grazioli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Di Martino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lecce</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Psychological impact of the quarantine-induced stress during the coronavirus (COVID-19) outbreak among Italian athletes</article-title>. <source>Int. J. Environ. Res. Public Health</source> <volume>17</volume> (<issue>23</issue>), <fpage>8867</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph17238867</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinarello</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Novick</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kaplanski</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Interleukin-18 and IL-18 binding protein</article-title>. <source>Front. Immunol.</source> <volume>4</volume>, <fpage>289</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2013.00289</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elliott</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Heron</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Grimstead</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Biswas</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Infographic. Graduated return to play guidance following COVID-19 infection</article-title>. <source>Br. J. Sports Med.</source> <volume>54</volume> (<issue>19</issue>), <fpage>1174</fpage>&#x2013;<lpage>1175</lpage>. <pub-id pub-id-type="doi">10.1136/bjsports-2020-102637</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>&#x3b2;2 Adrenergic receptor on T lymphocytes and its clinical implications</article-title>. <source>Prog. Nat. Sci.</source> <volume>19</volume> (<issue>1</issue>), <fpage>17</fpage>&#x2013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnsc.2008.10.001</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerrera</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Picozza</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>D&#x2019;Orso</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Placido</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pirronello</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Verdiani</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>BNT162b2 vaccination induces durable SARS-CoV-2&#x2013;specific T cells with a stem cell memory phenotype</article-title>. <source>Sci. Immunol.</source> <volume>6</volume> (<issue>66</issue>), <fpage>eabl5344</fpage>. <pub-id pub-id-type="doi">10.1126/sciimmunol.abl5344</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halle</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Binzenh&#xf6;fer</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mahrholdt</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Johannes Schindler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Esefeld</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tsch&#xf6;pe</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Myocarditis in athletes: A clinical perspective</article-title>. <source>Eur. J. Prev. Cardiol.</source> <volume>28</volume> (<issue>10</issue>), <fpage>1050</fpage>&#x2013;<lpage>1057</lpage>. <pub-id pub-id-type="doi">10.1177/2047487320909670</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jalkanen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kolehmainen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>H&#xe4;kkinen</surname>
<given-names>H. K.</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>T&#xe4;htinen</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Lundberg</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants</article-title>. <source>Nat. Commun.</source> <volume>12</volume> (<issue>1</issue>), <fpage>3991</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-24285-4</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Beggs</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Calder</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pearce</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Team Sport Risk Exposure Framework-2 (TS-REF-2) to identify sports activities and contacts at increased SARS-CoV-2 transmission risk during the COVID-19 pandemic</article-title>. <source>Br. J. Sports Med.</source> <volume>55</volume> (<issue>23</issue>), <fpage>1317</fpage>&#x2013;<lpage>1318</lpage>. <pub-id pub-id-type="doi">10.1136/bjsports-2021-104225</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khakroo Abkenar</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Rahmani-nia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The effects of acute and chronic aerobic activity on the signaling pathway of the inflammasome NLRP3 complex in young men</article-title>. <source>Med. Mex.</source> <volume>55</volume> (<issue>4</issue>), <fpage>105</fpage>. <pub-id pub-id-type="doi">10.3390/medicina55040105</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kokai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kashiwamura</surname>
<given-names>S. I.</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ohara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Morita</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Plasma interleukin-18 levels in patients with psychiatric disorders</article-title>. <source>J. Immunother.</source> <volume>25</volume>, <fpage>S68</fpage>&#x2013;<lpage>S71</lpage>. <pub-id pub-id-type="doi">10.1097/00002371-200203001-00011</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krzywa&#x144;ski</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mikulski</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Krysztofiak</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pokrywka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>M&#x142;y&#x144;czak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ma&#x142;ek</surname>
<given-names>&#x141;. A.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Elite athletes with COVID-19 &#x2014; predictors of the course of disease</article-title>. <source>J. Sci. Med. Sport</source> <volume>25</volume> (<issue>1</issue>), <fpage>9</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsams.2021.07.003</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leick</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lindegaard</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Stensvold</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Plomgaard</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Saltin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pilegaard</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Adipose tissue interleukin-18 mRNA and plasma interleukin-18: Effect of obesity and exercise</article-title>. <source>Obesity</source> <volume>15</volume> (<issue>2</issue>), <fpage>356</fpage>&#x2013;<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1038/oby.2007.528</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leung</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The younger the milder clinical course of COVID&#x2010;19: Even in newborns? Genuneit J, editor</article-title>. <source>Pediatr. Allergy Immunol.</source> <volume>32</volume> (<issue>2</issue>), <fpage>358</fpage>&#x2013;<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1111/pai.13371</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahnke</surname>
<given-names>Y. D.</given-names>
</name>
<name>
<surname>Brodie</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Sallusto</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Roederer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lugli</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>The who&#x27;s who of T-cell differentiation: Human memory T-cell subsets</article-title>. <source>Eur. J. Immunol.</source> <volume>43</volume> (<issue>11</issue>), <fpage>2797</fpage>&#x2013;<lpage>2809</lpage>. <pub-id pub-id-type="doi">10.1002/eji.201343751</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantovani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dinarello</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Molgora</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Garlanda</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Interleukin-1 and related cytokines in the regulation of inflammation and immunity</article-title>. <source>Immunity</source> <volume>50</volume> (<issue>4</issue>), <fpage>778</fpage>&#x2013;<lpage>795</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.012</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mee</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Alam</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Groves</surname>
<given-names>R. W.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Human keratinocytes constitutively produce but do not process interleukin-18</article-title>. <source>Br. J. Dermatol</source> <volume>143</volume> (<issue>2</issue>), <fpage>330</fpage>&#x2013;<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2133.2000.03759.x</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moss</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The T cell immune response against SARS-CoV-2</article-title>. <source>Nat. Immunol.</source> <volume>23</volume> (<issue>2</issue>), <fpage>186</fpage>&#x2013;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-021-01122-w</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mutsch</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Heiber</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gr&#xe4;tz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hain</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sch&#xf6;nfelder</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kaps</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Aerosol particle emission increases exponentially above moderate exercise intensity resulting in superemission during maximal exercise</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>119</volume> (<issue>22</issue>), <fpage>e2202521119</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2202521119</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nikseresht</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hafezi Ahmadi</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Hedayati</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Detraining-induced alterations in adipokines and cardiometabolic risk factors after nonlinear periodized resistance and aerobic interval training in obese men</article-title>. <source>Appl. Physiol. Nutr. Metab.</source> <volume>41</volume> (<issue>10</issue>), <fpage>1018</fpage>&#x2013;<lpage>1025</lpage>. <pub-id pub-id-type="doi">10.1139/apnm-2015-0693</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmowski</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gebhardt</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Reichel</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Frech</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ringseis</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Eder</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The impact of exercise serum on selected parameters of CD4&#x2b; T cell metabolism</article-title>. <source>Immuno</source> <volume>1</volume> (<issue>3</issue>), <fpage>119</fpage>&#x2013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.3390/immuno1030008</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pauser</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jantsch</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brem</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>SARS-CoV-2 transmission during an indoor professional sporting event</article-title>. <source>Sci. Rep.</source> <volume>11</volume> (<issue>1</issue>), <fpage>20723</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-99997-0</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phelan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>E. H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>A game plan for the resumption of sport and exercise after coronavirus disease 2019 (COVID-19) infection</article-title>. <source>JAMA Cardiol.</source> <volume>5</volume> (<issue>10</issue>), <fpage>1085</fpage>&#x2013;<lpage>1086</lpage>. <pub-id pub-id-type="doi">10.1001/jamacardio.2020.2136</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plomgaard</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Penkowa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>B. K.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Fiber type specific expression of TNF-alpha, IL-6 and IL-18 in human skeletal muscles</article-title>. <source>Exerc Immunol. Rev.</source> <volume>11</volume>, <fpage>53</fpage>&#x2013;<lpage>63</lpage>.</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raphael</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Nalawade</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Eagar</surname>
<given-names>T. N.</given-names>
</name>
<name>
<surname>Forsthuber</surname>
<given-names>T. G.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>T cell subsets and their signature cytokines in autoimmune and inflammatory diseases</article-title>. <source>Cytokine</source> <volume>74</volume> (<issue>1</issue>), <fpage>5</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2014.09.011</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Renner</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Geiselh&#xf6;ringer</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Fante</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bruss</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>F&#xe4;rber</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sch&#xf6;nhammer</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Metabolic plasticity of human T cells: Preserved cytokine production under glucose deprivation or mitochondrial restriction, but 2-deoxy-glucose affects effector functions</article-title>. <source>Eur. J. Immunol.</source> <volume>45</volume> (<issue>9</issue>), <fpage>2504</fpage>&#x2013;<lpage>2516</lpage>. <pub-id pub-id-type="doi">10.1002/eji.201545473</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robinson</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>O&#x2019;Garra</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Further checkpoints in Th1 development</article-title>. <source>Immunity</source> <volume>16</volume> (<issue>6</issue>), <fpage>755</fpage>&#x2013;<lpage>758</lpage>. <pub-id pub-id-type="doi">10.1016/s1074-7613(02)00331-x</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosendahl Huber</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>van Beek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>de Jonge</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luytjes</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>van Baarle</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>T cell responses to viral infections - opportunities for Peptide vaccination</article-title>. <source>Front. Immunol.</source> <volume>5</volume>, <fpage>171</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00171</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sallis</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Tartof</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Sallis</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Sall</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: A study in 48 440 adult patients</article-title>. <source>Br. J. Sports Med.</source> <volume>55</volume> (<issue>19</issue>), <fpage>1099</fpage>&#x2013;<lpage>1105</lpage>. <pub-id pub-id-type="doi">10.1136/bjsports-2021-104080</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savicevic</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Nincevic</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Versic</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cuschieri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bandalovic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Turic</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Performance of professional soccer players before and after COVID-19 infection; observational study with an emphasis on graduated return to play</article-title>. <source>Int. J. Environ. Res. Public Health</source> <volume>18</volume> (<issue>21</issue>), <fpage>11688</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph182111688</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schellhorn</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Klingel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Burgstahler</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Return to sports after COVID-19 infection</article-title>. <source>Eur. Heart J.</source> <volume>41</volume> (<issue>46</issue>), <fpage>4382</fpage>&#x2013;<lpage>4384</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehaa448</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slaats</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>ten Oever</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>van de Veerdonk</surname>
<given-names>F. L.</given-names>
</name>
<name>
<surname>Netea</surname>
<given-names>M. G.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>IL-1&#x3b2;/IL-6/CRP and IL-18/ferritin: Distinct inflammatory programs in infections</article-title>. <source>PLOS Pathog.</source> <volume>12</volume> (<issue>12</issue>), <fpage>e1005973</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1005973</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Bahnfleth</surname>
<given-names>W. P.</given-names>
</name>
<name>
<surname>Bluyssen</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Buonanno</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Jimenez</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Kurnitski</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Dismantling myths on the airborne transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)</article-title>. <source>J. Hosp. Infect.</source> <volume>110</volume>, <fpage>89</fpage>&#x2013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhin.2020.12.022</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vlahakos</surname>
<given-names>V. D.</given-names>
</name>
<name>
<surname>Marathias</surname>
<given-names>K. P.</given-names>
</name>
<name>
<surname>Arkadopoulos</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vlahakos</surname>
<given-names>D. V.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Hyperferritinemia in patients with COVID&#x2010;19: An opportunity for iron chelation?</article-title> <source>Artif. Organs</source> <volume>45</volume> (<issue>2</issue>), <fpage>163</fpage>&#x2013;<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1111/aor.13812</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Dysregulated CD4&#x2b; T cells and microRNAs in myocarditis</article-title>. <source>Front. Immunol.</source> <volume>11</volume>, <fpage>539</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.00539</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiskopf</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Raadsen</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Grifoni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Okba</surname>
<given-names>N. M. A.</given-names>
</name>
<name>
<surname>Endeman</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Phenotype and kinetics of SARS-CoV-2&#x2013;specific T cells in COVID-19 patients with acute respiratory distress syndrome</article-title>. <source>Sci. Immunol.</source> <volume>5</volume> (<issue>48</issue>), <fpage>eabd2071</fpage>. <pub-id pub-id-type="doi">10.1126/sciimmunol.abd2071</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Hull</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pollock</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dodd</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Haines</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Cardiorespiratory considerations for return-to-play in elite athletes after COVID-19 infection: A practical guide for sport and exercise medicine physicians</article-title>. <source>Br. J. Sports Med.</source> <volume>54</volume> (<issue>19</issue>), <fpage>1157</fpage>&#x2013;<lpage>1161</lpage>. <pub-id pub-id-type="doi">10.1136/bjsports-2020-102710</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Won</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gilotra</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Talor</surname>
<given-names>M. V.</given-names>
</name>
<name>
<surname>Lovell</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Increased interleukin 18-dependent immune responses are associated with myopericarditis after COVID-19 mRNA vaccination</article-title>. <source>Front. Immunol.</source> <volume>13</volume>, <fpage>851620</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.851620</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>